• A 56-year-old man presents to his primary care physician due to shortness of breath and fatigue. He reports that these symptoms have progressively worsened over the course of a few weeks. Medical history is significant for type II diabetes mellitus and chronic kidney disease with his last eGFR reading at 82 mL/min/1.73 m2. He has yet to need dialysis. Laboratory testing is significant for a hemaglobin of 9.5 g/dL and an eGFR of 55 mL/min/1.73 m2. After further evaluation of non-renal causes of anemia it was determined that erythropoietin should be added to his treatment regimen to improve his symptoms.
Mechanism of Action Clinical Use
  • IL-2 product which leads to
    • T-, B-cell, and NK cells
      • proliferation
      • differentiation
      • recruitment
  • Metastatic renal cell carcinoma
  • Metastatic melanoma
Erythropoietin (epoetin alfa)
  • Stimulates erythroid progenitor cells to
    • divide and differentiate
  • Anemia
  • Granulocyte colony stimulating factors to result in neutrophil
    • proliferation
    • differentiation
    • activation
  • To recover
    • white count and bone marrow
  • Granulocyte macrophage colony stimulating factor to result in neutrophil and monocyte
    • proliferation
    • differentiation
    • activation
  • Multiple effects
  • Chronic hepatitis B and C
  • Malignant melanoma
  • Condyloma acuminatum
  • Hairy cell leukemia
  • Kaposi sarcoma
  • Multiple sclerosis
  • Chronic granulomatous disease
Romiplostim (thrombopoietin)
  • A thrombopoietin (TPO) analog that acts on the TPO receptor to
    • ↑ platelet count
  • Thrombocytopenia
  • A TPO agonist that leads to
    • ↑ platelet count
  • Thrombocytopenia
Oprelvekin (IL-11)
  • A thrombopoietic growth factor that results in
    • ↑ platelet count
  • Thrombocytopenia

Please rate topic.

Average 5.0 of 1 Ratings

Questions (1)
Topic COMMENTS (0)
Private Note